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Inappropriate antibiotic use is one of the major health
problems worldwide.1,2 In Europe and the USA, acute respiratory
tract infections account for almost 75% of antimicrobial prescrip-
tions each year, despite their mainly viral etiology.3 In the
emergency department (ED), the physician is often left with
diagnostic uncertainty because of the lack of speciﬁcity of clinical
signs, symptoms, and laboratory markers. Thus, acute respiratory
tract infections are important targets for strategies aimed at
decreasing antibiotic consumption.4 The French National Author-
ity for Health recommends a restrictive antimicrobial policy,
including early antimicrobial prescription reassessment.5 Thus,
we carried out a pilot study in order to evaluate the effect of early
reassessment of initial antimicrobial prescription for inpatients
with acute respiratory tract infections.
Our prospective, interventional study, based on an intention-
to-treat analysis, took place at the Teaching Hospital of the city of
Nantes, France. All consecutive patients aged 18 years or older who
presented to the ED with an acute respiratory tract infection, who
were prescribed antibiotics by an ED physician and who were then
hospitalised in a 22-bed medical ward were eligible for inclusion.
All the included patients were examined by a senior pneumologist
during the ﬁrst 24 h of the hospitalization for a reassessment of the
initial ED diagnostic and of the initial antimicrobial prescriptions.
The appropriateness of antimicrobial prescription was determined
using a standardized method based on current practice guide-
lines.6,7 Antibiotics were immediately withdrawn in patients with
antimicrobial prescriptions classiﬁed as inappropriate. The prima-
ry objective of our study was to evaluate the appropriateness of theTable 1
Baseline characteristics of the study population.
Demographics
Age, years
Mean (SD) 76 (16)
Male sex 30 (48%)
Coexisting illnesses
Coronary heart disease 14 (22%)
Hepatopathy 2 (3%)
Renal dysfunction 4 (6%)
COPD 10 (16%)
Diabetes 8 (12%)
Neoplastic disease 5 (8%)
Immunodepression 8 (12%)
ED diagnosis
Community-acquired pneumonia 45 (72%)
Exacerbation of COPD 7 (11%)
Acute bronchitis 11 (17%)
Results are n (%) unless stated otherwise. COPD, chronic obstructive pulmonary
disease; SD, standard deviation.
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was the proportion of patients with antibiotics prescribed
inappropriately in the ED. The second objective of our study
was to evaluate the effectiveness and the accuracy of the
intervention. The secondary outcome measure was a composite
of overall adverse events related to the initial acute respiratory
tract infection occurring within 30 days following the ED
admission.
During the 1-year study period, a total of 63 patients were
included. The clinical characteristics of the population are listed
in Table 1. ED antimicrobial prescriptions were reviewed during
the ﬁrst 24 h of the hospitalization. Initial antimicrobial
prescriptions were considered inappropriate and withdrawn
in the case of 15 patients (24%). All the 15 patients were free of
any adverse event related to the initial diagnosis within a 30-
day follow-up.
To our knowledge, our pilot study was the ﬁrst designed to
evaluate a new intervention in order to reduce antibiotic
consumption: early reassessment, during the ﬁrst 24 h of the
hospitalization, of the initial ED antimicrobial prescription in
acute respiratory tract infection. Our data indicate that
antimicrobial prescriptions in the ED were relatively inappro-
priate. Moreover, our ﬁndings support the fact that early
reassessment of the ED antimicrobial prescription was an
accurate and effective intervention, encouraging more research
in this ﬁeld.
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